Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) – Equities researchers at Leerink Partnrs reduced their FY2027 EPS estimates for Cytokinetics in a research note issued on Wednesday, May 22nd. Leerink Partnrs analyst R. Ruiz now anticipates that the biopharmaceutical company will earn $3.85 per share for the year, down from their previous forecast of $4.20. The […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective decreased by Raymond James from $92.00 to $70.00 in a research note released on Thursday, Benzinga reports. Raymond James currently has an outperform rating on the biopharmaceutical company’s stock. Other analysts have also recently issued reports about the company. Truist Financial reissued a buy rating and […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective cut by Needham & Company LLC from $108.00 to $72.00 in a report released on Thursday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Other analysts also recently issued reports about the company. JMP Securities reduced their price objective on […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its price target reduced by Needham & Company LLC from $108.00 to $72.00 in a research report report published on Thursday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. A number of other analysts have also recently issued reports on CYTK. Mizuho reduced […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its price target lowered by HC Wainwright from $94.00 to $90.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. CYTK has been the topic of several other research reports. JMP Securities reduced their price target on shares […]